Results 81 to 90 of about 1,567 (130)

Clinical evidence supporting ceftaroline fosamil and ceftobiprole for complicated skin and soft tissue infections

, 2023
Purpose of review: Ceftaroline and ceftobiprole are advanced generation cephalosporins with activity against methicillin-resistant Staphylococcus aureus (MRSA).
Leventogiannis, K., Giamarellos-Bourboulis, E.J., Mouktaroudi, M.   +2 more
core   +1 more source

Comparative pharmacoeconomic analysis of ceffaroline fosamil in the treatment of complicated skin and soft tissues infections

Качественная клиническая практика, 2018
The objective was to evaluate the cost-effectiveness and budget impact of ceftaroline fosamil compared with other intravenous antibiotics with anti-MRSA activity in the treatment of complicated skin and soft tissue infections (cSSTI).
S. K. Zyryanov, D. Yu. Belousov, E. V. Afanasyeva   +2 more
doaj  

Ceftaroline fosamil: clinical experience after 23-month prescription in a tertiary hospital. [PDF]

Rev Esp Quimioter, 2021
Alonso Álvarez A, Ramos Merino L, Castelo Corral LM, Padín Trigo A, Sousa Regueiro D, Míguez Rey E, Sánchez Vidal E.   +6 more
europepmc   +1 more source

Interaction of Ceftaroline with Clinically-Relevant β-Lactamases

, 2015
Background: Ceftaroline fosamil is a cephalosporin approved for community-acquired pneumonia and acute bacterial skin and skin structure infections. Ceftaroline, the active metabolite of ceftaroline fosamil, has broad-spectrum in vitro activity against ...
DE LUCA, FILOMENA, DOCQUIER, JEAN DENIS, ROSSOLINI, GIAN MARIA   +2 more
core   +1 more source

Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials. [PDF]

Infect Dis Ther, 2022
Wilcox M, Yan JL, Gonzalez PL, Dryden M, Stone GG, Kantecki M.   +5 more
europepmc   +1 more source

Comparative effectiveness and safety of six antibiotics in treating MRSA infections: A network meta-analysis

International Journal of Infectious Diseases
Objectives: This study conducted a network meta-analysis comparing linezolid, teicoplanin, daptomycin, tigecycline, and ceftaroline fosamil with vancomycin for treating MRSA-related diseases, addressing the lack of comprehensive evaluations in existing ...
Gehang Ju, Yan Zhang, Chao Ye, Qiong Liu, Hanzhu Sun, Zhaorui Zhang, Xinyi Huang, Yueping Jiang, Qi Huang   +8 more
doaj   +1 more source

Ceftaroline in complicated skin and skin-structure infections

, 2012
Paul O Hernandez1, Sergio Lema2, Stephen K Tyring3, Natalia Mendoza2,41University of Texas School of Medicine at San Antonio, San Antonio, TX, 2Woodhull Medical and Mental Health Center, Brooklyn, NY, 3Department of Dermatology, University of Texas ...
Tyring SK, Lema S, Hernandez PO, Mendoza N   +3 more
core   +1 more source

Heartfelt Impact: A Descriptive Analysis of Ceftaroline-Containing Regimens in Endocarditis due to Methicillin-Resistant Staphylococcus aureus

Infectious Diseases and Therapy
Introduction Infective endocarditis (IE) due to methicillin-resistant Staphylococcus aureus (MRSA) is characterized by frequent treatment failure to first-line agents and high mortality, necessitating use of alternative management strategies. Ceftaroline
Kaylee E. Caniff, Chloe Judd, Kristen Lucas, Sandra Goro, Caroline Orzol, Mirna Eshaya, Mohammed Al Musawa, Michael P. Veve, Michael J. Rybak   +8 more
doaj   +1 more source

Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: a matched cohort study

, 2016
OBJECTIVES: There are few convenient intravenous options for long-term outpatient treatment of osteoarticular infection (OAI) and limited effectiveness and safety data exist for this off-label use of ceftaroline.
Davis, Susan L, Kenney, Rachel M, Wong, Jacob, Athans, Vasilios   +3 more
core   +1 more source

Successful Treatment of Refractory Methicillin-Sensitive Staphylococcus aureus Osteomyelitis With Ceftaroline Fosamil in a Diabetic Patient. [PDF]

Cureus
Baroud S, Alhammadi F, Alhashimi F, Elhaout J, Al-Shakerchi H.   +4 more
europepmc   +1 more source